Nasal swab may predict who benefits from cystic fibrosis drug

This study looked at whether a test using cells from the nose can predict how well the drug Orkambi works for people with cystic fibrosis. Researchers collected nasal cells from 91 participants before treatment and measured how the drug improved cell function. They then compared these lab results to actual breathing improvements after 24 weeks of taking Orkambi. The goal is to develop a personalized way to identify which patients will benefit most from the therapy.